Licensing · Southeast Asia · Announced 14 Oct 2026

Nxera Pharma → Synmosa Biopharma

Nxera Pharma granted Taiwan's Synmosa Biopharma exclusive rights to license, supply and commercialise the insomnia drug QUVIVIQ (daridorexant) in six Southeast Asian markets plus Australia and New Zealand.

Parties: Nxera Pharma (Japan) → Synmosa Biopharma (Taiwan)

Deal type
Licensing
Value
Undisclosed
Territory
Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam, Australia, New Zealand
Therapeutic area
CNS / Neurology
Asset
QUVIVIQ (daridorexant)
Announced
14 Oct 2026

Our analysis

Why this matters

Nxera Pharma announced on 14 October 2026 an exclusive license, supply and commercialization agreement with Synmosa Biopharma for QUVIVIQ (daridorexant), a dual orexin receptor antagonist for insomnia, in eight markets: Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia and New Zealand. Nxera receives an upfront payment, regulatory milestones, royalties and drug-supply revenue; amounts were not disclosed.

Daridorexant was discovered by Idorsia and is already marketed in Japan and approved in Taiwan, with an application under review in South Korea. Launches in the new markets depend on local approvals.

The full analysis is free to read with a work email on this page.

Source: Nxera Pharma press release (GlobeNewswire)

Latest deals

All Southeast Asia deals → · All licensing deals → · Browse all emerging-market pharma deals →